Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy

Science Translational Medicine

Volumn 9, Issue 410, 2017, Pages

  Pinter, Matthias ^a,b   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; C REACTIVE PROTEIN; CD40 ANTIGEN; COLLAGEN TYPE 1; COLONY STIMULATING FACTOR 1; CYCLOOXYGENASE 2; ENDOTHELIN 1; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; APOPTOSIS; CANCER ASSOCIATED FIBROBLAST; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELL PROLIFERATION; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; ENZYME ACTIVITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREATIC STELLATE CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; REVIEW; TUMOR MICROENVIRONMENT; URINARY TRACT CANCER; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); VASCULARIZATION;

ANIMALS; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RENIN-ANGIOTENSIN SYSTEM; TUMOR MICROENVIRONMENT;

EID: 85030552074     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aan5616     Document Type: Review

References (197)

1. E. I. Ager, J. Neo, C. Christophi, The renin-angiotensin system and malignancy. Carcinogenesis 29, 1675-1684 (2008)
2. M. Bader, Tissue renin-angiotensin-aldosterone systems: Targets for pharmacological therapy. Annu. Rev. Pharmacol. Toxicol. 50, 439-465 (2010)
3. M. Gasparo, K. J. Catt, T. Inagami, J. W. Wright, T. Unger, International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52, 415-472 (2000)
4. A. J. George, W. G. Thomas, R. D. Hannan, The renin-angiotensin system and cancer: Old dog, new tricks. Nat. Rev. Cancer 10, 745-759 (2010)
5. M. Paul, A. Poyan Mehr, R. Kreutz, Physiology of local renin-angiotensin systems. Physiol. Rev. 86, 747-803 (2006)
6. T. Qaradakhi, V. Apostolopoulos, A. Zulli, Angiotensin (1-7) and alamandine: Similarities and differences. Pharmacol. Res. 111, 820-826 (2016)
7. S. Rodrigues-Ferreira, C. Nahmias, G-protein coupled receptors of the renin-angiotensin system: New targets against breast cancer? Front. Pharmacol. 6, 24 (2015)
8. H. Kobori, M. Nangaku, L. G. Navar, A. Nishiyama, The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59, 251-287 (2007)
9. C. M. Ferrario, Role of angiotensin II in cardiovascular disease-Therapeutic implications of more than a century of research. J. Renin Angiotensin Aldosterone Syst. 7, 3-14 (2006)
10. D. W. Cushman, M. A. Ondetti, History of the design of captopril and related inhibitors of angiotensin converting enzyme. Hypertension 17, 589-592 (1991)
11. G. Bhardwaj, How the antihypertensive losartan was discovered. Expert Opin. Drug Discov. 1, 609-618 (2006)
12. P. Ponikowski, A. A. Voors, S. D. Anker, H. Bueno, J. G. F. Cleland, A. J. S. Coats, V. Falk, J. R. González-Juanatey, V.-P. Harjola, E. A. Jankowska, M. Jessup, C. Linde, P. Nihoyannopoulos, J. T. Parissis, B. Pieske, J. P. Riley, G. M. C. Rosano, L. M. Ruilope, F. Ruschitzka, F. H. Rutten, P. van der Meer; Authors/Task Force Members, 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 37, 2129-2200 (2016)
13. P. A. James, S. Oparil, B. L. Carter, W. C. Cushman, C. Dennison-Himmelfarb, J. Handler, D. T. Lackland, M. L. LeFevre, T. D. MacKenzie, O. Ogedegbe, S. C. Smith Jr., L. P. Svetkey, S. J. Taler, R. R. Townsend, J. T. Wright Jr., A. S. Narva, E. Ortiz, 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507-520 (2014)
14. A. Levin, P. E. Stevens, Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 85, 49-61 (2014)
15. P. T. O'Gara, F. G. Kushner, D. D. Ascheim, D. E. Casey Jr., M. K. Chung, J. A. de Lemos, S. M. Ettinger, J. C. Fang, F. M. Fesmire, B. A. Franklin, C. B. Granger, H. M. Krumholz, J. A. Linderbaum, D. A. Morrow, L. K. Newby, J. P. Ornato, N. Ou, M. J. Radford, J. E. Tamis-Holland, C. L. Tommaso, C. M. Tracy, Y. J. Woo, D. X. Zhao, J. L. Anderson, A. K. Jacobs, J. L. Halperin, N. M. Albert, R. G. Brindis, M. A. Creager, D. DeMets, R. A. Guyton, J. S. Hochman, R. J. Kovacs, E. M. Ohman, W. G. Stevenson, C. W. Yancy; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: A report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. Circulation 127, e362-e425 (2013)
16. M. M. Shafiq, D. V. Menon, R. G. Victor, Oral direct renin inhibition: Premise, promise, and potential limitations of a new antihypertensive drug. Am. J. Med. 121, 265-271 (2008)
17. I. Sipahi, S. M. Debanne, D. Y. Rowland, D. I. Simon, J. C. Fang, Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol. 11, 627-636 (2010)
18. ARB Trialists Collaboration, Effects of telmisartan, irbesartan, valsartan, candesartan, and losartan on cancers in 15 trials enrolling 138,769 individuals. J. Hypertens. 29, 623-635 (2011)
19. S. Bangalore, S. Kumar, S. E. Kjeldsen, H. Makani, E. Grossman, J. Wetterslev, A. K. Gupta, P. S. Sever, C. Gluud, F. H. Messerli, Antihypertensive drugs and risk of cancer: Network meta-analyses and trial sequential analyses of 324,168 participants from randomised trials. Lancet Oncol. 12, 65-82 (2011)
20. FDA Drug Safety Communication: No increase in risk of cancer with certain blood pressure drugs-Angiotensin Receptor Blockers (ARBs), 15 July 2010; www.fda.gov/ Drugs/DrugSafety/ucm257516.htm
21. W. T. Link, A. Felice, An FDA overview of rodent carcinogenicity studies of angiotensin II AT-1 receptor blockers: Pulmonary adenomas and carcinomas. Regul. Toxicol. Pharmacol. 70, 555-563 (2014)
22. V. P. Chauhan, J. D. Martin, H. Liu, D. A. Lacorre, S. R. Jain, S. V. Kozin, T. Stylianopoulos, A. S. Mousa, X. Han, P. Adstamongkonkul, Z. Popovi?, P. Huang, M. G. Bawendi, Y. Boucher, R. K. Jain, Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat. Commun. 4, 2516 (2013)
23. J. E. Murphy, J. Y.-L. Wo, C. Ferrone, W. Jiang, B. Y. Yeap, L. S. Blaszkowsky, E. L. Kwak, J. N. Allen, J. W. Clark, J. E. Faris, A. X. Zhu, L. Goyal, H. J. Mamon, K. D. Lillemoe, D. P. Ryan, T. F. DeLaney, C. Fernandez-Castillo, Y. Boucher, T. S. Hong, TGF-B1 inhibition with losartan in combination with FOLFIRINOX (F-NOX) in locally advanced pancreatic cancer (LAPC): Preliminary feasibility and R0 resection rates from a prospective phase II study. J. Clin. Oncol. 35 (suppl. 4S), 386 (2017)
24. H. Liu, K. Naxerova, M. Pinter, J. Incio, H. Lee, K. Shigeta, W. W. Ho, J. A. Crain, A. Jacobson, T. Michelakos, D. Dias-Santos, A. Zanconato, T. S. Hong, J. W. Clark, J. E. Murphy, D. P. Ryan, V. Deshpande, K. D. Lillemoe, C. Fernandez-Castillo, M. Downes, R. M. Evans, J. Michaelson, C. R. Ferrone, Y. Boucher, R. K. Jain, Use of angiotensin system inhibitors is associated with immune activation and longer survival in non-metastatic pancreatic ductal adenocarcinoma. Clin. Cancer Res. (2017)
25. O. Arrieta, B. Pineda-Olvera, P. Guevara-Salazar, N. Hernández-Pedro, D. Morales-Espinosa, T. L. Cerón-Lizarraga, C. H. González-Rosa, D. Rembao, B. Segura-Pacheco, J. Sotelo, Expression of AT1 and AT2 angiotensin receptors in astrocytomas is associated with poor prognosis. Br. J. Cancer 99, 160-166 (2008)
26. O. Arrieta, C. Villarreal-Garza, G. Vizcaíno, B. Pineda, N. Hernández-Pedro, P. Guevara-Salazar, T. Wegman-Ostrosky, G. Villanueva-Rodríguez, A. Gamboa-Domínguez, Association between AT1 and AT2 angiotensin II receptor expression with cell proliferation and angiogenesis in operable breast cancer. Tumour Biol. 36, 5627-5634 (2015)
27. K. Ino, K. Shibata, H. Kajiyama, E. Yamamoto, T. Nagasaka, A. Nawa, S. Nomura, F. Kikkawa, Angiotensin II type 1 receptor expression in ovarian cancer and its correlation with tumour angiogenesis and patient survival. Br. J. Cancer 94, 552-560 (2006)
28. C. Rocken, F. W. Rohl, E. Diebler, U. Lendeckel, M. Pross, S. Carl-McGrath, M. P. Ebert, The angiotensin II/angiotensin II receptor system correlates with nodal spread in intestinal type gastric cancer. Cancer Epidemiol. Biomarkers Prev. 16, 1206-1212 (2007)
29. S. Shirotake, A. Miyajima, T. Kosaka, N. Tanaka, T. Maeda, E. Kikuchi, M. Oya, Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology 77, 1009.e19-1009.e25 (2011)
30. I. V. Balyasnikova, S. M. Danilov, V. R. Muzykantov, A. B. Fisher, Modulation of angiotensin-converting enzyme in cultured human vascular endothelial cells. In Vitro Cell. Dev. Biol. Anim. 34, 545-554 (1998)
31. S. M. Danilov, E. Sadovnikova, N. Scharenborg, I. V. Balyasnikova, D. A. Svinareva, E. L. Semikina, E. N. Parovichnikova, V. G. Savchenko, G. J. Adema, Angiotensinconverting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemiaderived dendritic cells. Exp. Hematol. 31, 1301-1309 (2003)
32. C. Lin, V. Datta, D. Okwan-Duodu, X. Chen, S. Fuchs, R. Alsabeh, S. Billet, K. E. Bernstein, X. Z. Shen, Angiotensin-converting enzyme is required for normal myelopoiesis. FASEB J. 25, 1145-1155 (2011)
33. X. Z. Shen, S. Billet, C. Lin, D. Okwan-Duodu, X. Chen, A. E. Lukacher, K. E. Bernstein, The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat. Immunol. 12, 1078-1085 (2011)
34. V. Cortez-Retamozo, M. Etzrodt, A. Newton, R. Ryan, F. Pucci, S. W. Sio, W. Kuswanto, P. J. Rauch, A. Chudnovskiy, Y. Iwamoto, R. Kohler, B. Marinelli, R. Gorbatov, G. Wojtkiewicz, P. Panizzi, M. Mino-Kenudson, R. Forghani, J.-L. Figueiredo, J. W. Chen, R. Xavier, F. K. Swirski, M. Nahrendorf, R. Weissleder, M. J. Pittet, Angiotensin II drives the production of tumor-promoting macrophages. Immunity 38, 296-308 (2013)
35. H. Azevedo, A. Fujita, S. Y. Bando, P. Iamashita, C. A. Moreira-Filho, Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression. PLOS ONE 9, e110934 (2014)
36. X. Li, H. Zhang, V. Soledad-Conrad, J. Zhuang, B. D. Uhal, Bleomycin-induced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am. J. Physiol. Lung Cell. Mol. Physiol. 284, L501-L507 (2003)
37. L. Nguyen, E. I. Ager, J. Neo, C. Christophi, Regulation of colorectal cancer cell epithelial to mesenchymal transition by the renin angiotensin system. J. Gastroenterol. Hepatol. 31, 1773-1782 (2016)
38. M. Papp, X. Li, J. Zhuang, R. Wang, B. D. Uhal, Angiotensin receptor subtype AT1 mediates alveolar epithelial cell apoptosis in response to ANG II. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L713-L718 (2002)
39. S. Zheng, Y. Yang, R. Song, X. Yang, H. Liu, Q. Ma, L. Yang, R. Meng, T. Tao, S. Wang, J. He, Ang-(1-7) promotes the migration and invasion of human renal cell carcinoma cells via Mas-mediated AKT signaling pathway. Biochem. Biophys. Res. Commun. 460, 333-340 (2015)
40. M. J. Smyth, S. F. Ngiow, A. Ribas, M. W. L. Teng, Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143-158 (2016)
41. D. H. Munn, V. Bronte, Immune suppressive mechanisms in the tumor microenvironment. Curr. Opin. Immunol. 39, 1-6 (2016)
42. B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher, R. K. Jain, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc. Natl. Acad. Sci. U.S.A. 108, 2909-2914 (2011)
43. D. Öhlund, E. Elyada, D. Tuveson, Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503-1523 (2014)
44. M. O. Li, R. A. Flavell, TGF-b: A master of all T cell trades. Cell 134, 392-404 (2008)
45. J. Watt, H. M. Kocher, The desmoplastic stroma of pancreatic cancer is a barrier to immune cell infiltration. OncoImmunology 2, e26788 (2013)
46. R. K. Jain, Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J. Clin. Oncol. 31, 2205-2218 (2013)
47. R. K. Jain, J. D. Martin, T. Stylianopoulos, The role of mechanical forces in tumor growth and therapy. Annu. Rev. Biomed. Eng. 16, 321-346 (2014)
48. R. K. Jain, Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. Cancer Cell 26, 605-622 (2014)
49. M. Z. Noman, M. Hasmim, Y. Messai, S. Terry, C. Kieda, B. Janji, S. Chouaib, Hypoxia: A key player in antitumor immune response. A review in the theme: Cellular responses to hypoxia. Am. J. Physiol. Cell Physiol. 309, C569-C579 (2015)
50. A. Palazón, J. Aragonés, A. Morales-Kastresana, M. O. Landázuri, I. Melero, Molecular pathways: Hypoxia response in immune cells fighting or promoting cancer. Clin. Cancer Res. 18, 1207-1213 (2012)
51. T. Voron, O. Colussi, E. Marcheteau, S. Pernot, M. Nizard, A.-L. Pointet, S. Latreche, S. Bergaya, N. Benhamouda, C. Tanchot, C. Stockmann, P. Combe, A. Berger, F. Zinzindohoue, H. Yagita, E. Tartour, J. Taieb, M. Terme, VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors. J. Exp. Med. 212, 139-148 (2015)
52. Y. Chen, R. R. Ramjiawan, T. Reiberger, M. R. Ng, T. Hato, Y. Huang, H. Ochiai, S. Kitahara, E. C. Unan, T. P. Reddy, C. Fan, P. Huang, N. Bardeesy, A. X. Zhu, R. K. Jain, D. G. Duda, CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology 61, 1591-1602 (2015)
53. C. Feig, J. O. Jones, M. Kraman, R. J. B. Wells, A. Deonarine, D. S. Chan, C. M. Connell, E. W. Roberts, Q. Zhao, O. L. Caballero, S. A. Teichmann, T. Janowitz, D. I. Jodrell, D. A. Tuveson, D. T. Fearon, Targeting CXCL12 from FAP-expressing carcinomaassociated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc. Natl. Acad. Sci. U.S.A. 110, 20212-20217 (2013)
54. H. Jiang, S. Hegde, B. L. Knolhoff, Y. Zhu, J. M. Herndon, M. A. Meyer, T. M. Nywening, W. G. Hawkins, I. M. Shapiro, D. T. Weaver, J. A. Pachter, A. Wang-Gillam, D. G. DeNardo, Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy. Nat. Med. 22, 851-860 (2016)
55. A. Masamune, S. Hamada, K. Kikuta, T. Takikawa, S. Miura, E. Nakano, T. Shimosegawa, The angiotensin II type I receptor blocker olmesartan inhibits the growth of pancreatic cancer by targeting stellate cell activities in mice. Scand. J. Gastroenterol. 48, 602-609 (2013)
56. M. Okazaki, S. Fushida, S. Harada, T. Tsukada, J. Kinoshita, K. Oyama, H. Tajima, I. Ninomiya, T. Fujimura, T. Ohta, The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer. Cancer Lett. 355, 46-53 (2014)
57. C. Godugu, A. R. Patel, R. Doddapaneni, S. Marepally, T. Jackson, M. Singh, Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models. J. Control. Release 172, 86-95 (2013)
58. K. Patel, R. Doddapaneni, N. Chowdhury, C. H. A. Boakye, G. Behl, M. Singh, Tumor stromal disrupting agent enhances the anticancer efficacy of docetaxel loaded PEGylated liposomes in lung cancer. Nanomedicine 11, 1377-1392 (2016)
59. J. Incio, H. Liu, P. Suboj, S. M. Chin, I. X. Chen, M. Pinter, M. R. Ng, H. T. Nia, J. Grahovac, S. Kao, S. Babykutty, Y. Huang, K. Jung, N. N. Rahbari, X. Han, V. P. Chauhan, J. D. Martin, J. Kahn, P. Huang, V. Desphande, J. Michaelson, T. P. Michelakos, C. R. Ferrone, R. Soares, Y. Boucher, D. Fukumura, R. K. Jain, Obesity-induced inflammation and desmoplasia promote pancreatic cancer progression and resistance to chemotherapy. Cancer Discov. 6, 852-869 (2016)
60. S. A. Arnold, L. B. Rivera, J. G. Carbon, J. E. Toombs, C.-L. Chang, A. D. Bradshaw, R. A. Brekken, Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGFb activation. PLOS ONE 7, e31384 (2012)
61. R. Anandanadesan, Q. Gong, G. Chipitsyna, A. Witkiewicz, C. J. Yeo, H. A. Arafat, Angiotensin II induces vascular endothelial growth factor in pancreatic cancer cells through an angiotensin II type 1 receptor and ERK1/2 signaling. J. Gastrointest. Surg. 12, 57-66 (2008)
62. Y. Ji, Z. Wang, Z. Li, K. Li, X. Le, T. Zhang, Angiotensin II induces angiogenic factors production partly via AT1/JAK2/STAT3/SOCS3 signaling pathway in MHCC97H cells. Cell. Physiol. Biochem. 29, 863-874 (2012)
63. T. Kosaka, A. Miyajima, S. Shirotake, E. Kikuchi, M. Hasegawa, S. Mikami, M. Oya, Ets-1 and hypoxia inducible factor-1alpha inhibition by angiotensin II type-1 receptor blockade in hormone-refractory prostate cancer. Prostate 70, 162-169 (2010)
64. M. Fujita, I. Hayashi, S. Yamashina, A. Fukamizu, M. Itoman, M. Majima, Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 26, 271-279 (2005)
65. M. Kosugi, A. Miyajima, E. Kikuchi, Y. Horiguchi, M. Murai, Angiotensin II type 1 receptor antagonist candesartan as an angiogenic inhibitor in a xenograft model of bladder cancer. Clin. Cancer Res. 12, 2888-2893 (2006)
66. H. Yoshiji, S. Kuriyama, M. Kawata, J. Yoshii, Y. Ikenaka, R. Noguchi, T. Nakatani, H. Tsujinoue, H. Fukui, The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: Possible role of the vascular endothelial growth factor. Clin. Cancer Res. 7, 1073-1078 (2001)
67. R. K. Jain, Determinants of tumor blood flow: A review. Cancer Res. 48, 2641-2658 (1988)
68. Y. Huang, S. Goel, D. G. Duda, D. Fukumura, R. K. Jain, Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 73, 2943-2948 (2013)
69. Y. Huang, J. Yuan, E. Righi, W. S. Kamoun, M. Ancukiewicz, J. Nezivar, M. Santosuosso, J. D. Martin, M. R. Martin, F. Vianello, P. Leblanc, L. L. Munn, P. Huang, D. G. Duda, D. Fukumura, R. K. Jain, M. C. Poznansky, Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 109, 17561-17566 (2012)
70. T. T. Batchelor, E. R. Gerstner, K. E. Emblem, D. G. Duda, J. Kalpathy-Cramer, M. Snuderl, M. Ancukiewicz, P. Polaskova, M. C. Pinho, D. Jennings, S. R. Plotkin, A. S. Chi, A. F. Eichler, J. Dietrich, F. H. Hochberg, C. Lu-Emerson, A. J. Iafrate, S. P. Ivy, B. R. Rosen, J. S. Loeffler, P. Y. Wen, A. G. Sorensen, R. K. Jain, Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc. Natl. Acad. Sci. U.S.A. 110, 19059-19064 (2013)
71. K. E. Emblem, K. Mouridsen, A. Bjornerud, C. T. Farrar, D. Jennings, R. J. H. Borra, P. Y. Wen, P. Ivy, T. T. Batchelor, B. R. Rosen, R. K. Jain, A. G. Sorensen, Vessel architectural imaging identifies cancer patient responders to anti-angiogenic therapy. Nat. Med. 19, 1178-1183 (2013)
72. A. G. Sorensen, K. E. Emblem, P. Polaskova, D. Jennings, H. Kim, M. Ancukiewicz, M. Wang, P. Y. Wen, P. Ivy, T. T. Batchelor, R. K. Jain, Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res. 72, 402-407 (2012)
73. R. E. Gilbert, D. J. Kelly, A. J. Cox, J. L. Wilkinson-Berka, J. R. Rumble, T. Osicka, S. Panagiotopoulos, V. Lee, E. C. Hendrich, G. Jerums, M. E. Cooper, Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes. Diabetologia 43, 1360-1367 (2000)
74. H. Sano, K. Hosokawa, H. Kidoya, N. Takakura, Negative regulation of VEGF-induced vascular leakage by blockade of angiotensin II type 1 receptor. Arterioscler. Thromb. Vasc. Biol. 26, 2673-2680 (2006)
75. K. E. Emblem, E. R. Gerstner, G. Sorensen, B. R. Rosen, P. Y. Wen, T. T. Batchelor, R. K. Jain, Abstract 3975: Matrix-depleting anti-hypertensives decompress tumor blood vessels and improve perfusion in patients with glioblastoma receiving anti-angiogenic therapy. Cancer Res. 76 (suppl. 14), 3975 (2016)
76. K. M. Bell, V. E. Prise, K. M. Shaffi, D. J. Chaplin, G. M. Tozer, A comparative study of tumour-blood-flow modification in two rat-tumour systems using endothelin-1 and angiotensin II: Influence of tumour size on angiotensin-II response. Int. J. Cancer 67, 730-738 (1996)
77. G. M. Tozer, K. M. Shaffi, The response of tumour vasculature to angiotensin II revealed by its systemic and local administration to 'tissue-isolated' tumours. Br. J. Cancer 72, 595-600 (1995)
78. R. A. Zlotecki, L. T. Baxter, Y. Boucher, R. K. Jain, Pharmacologic modification of tumor blood flow and interstitial fluid pressure in a human tumor xenograft: Network analysis and mechanistic interpretation. Microvasc. Res. 50, 429-443 (1995)
79. R. A. Zlotecki, Y. Boucher, I. Lee, L. T. Baxter, R. K. Jain, Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res. 53, 2466-2468 (1993)
80. O. Thews, D. K. Kelleher, P. Vaupel, Disparate responses of tumour vessels to angiotensin II: Tumour volume-dependent effects on perfusion and oxygenation. Br. J. Cancer 83, 225-231 (2000)
81. D. Okwan-Duodu, J. Landry, X. Z. Shen, R. Diaz, Angiotensin-converting enzyme and the tumor microenvironment: Mechanisms beyond angiogenesis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 305, R205-R215 (2013)
82. F. R. Balkwill, A. Mantovani, Cancer-related inflammation: Common themes and therapeutic opportunities. Semin. Cancer Biol. 22, 33-40 (2012)
83. Y. Ji, Z. Wang, Z. Li, A. Zhang, Y. Jin, H. Chen, X. Le, Angiotensin II enhances proliferation and inflammation through AT1/PKC/NF-kB signaling pathway in hepatocellular carcinoma cells. Cell. Physiol. Biochem. 39, 13-32 (2016)
84. H. Uemura, H. Ishiguro, Y. Nagashima, T. Sasaki, N. Nakaigawa, H. Hasumi, S. Kato, Y. Kubota, Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol. Cancer Ther. 4, 1699-1709 (2005)
85. T. Matsuzuka, K. Miller, L. Pickel, C. Doi, R. Ayuzawa, M. Tamura, The synergistic induction of cyclooxygenase-2 in lung fibroblasts by angiotensin II and pro-inflammatory cytokines. Mol. Cell. Biochem. 320, 163-171 (2009)
86. H. Pham, B. Chong, R. Vincenti, L. W. Slice, Ang II and EGF synergistically induce COX-2 expression via CREB in intestinal epithelial cells. J. Cell. Physiol. 214, 96-109 (2008)
87. L. W. Slice, T. Chiu, E. Rozengurt, Angiotensin II and epidermal growth factor induce cyclooxygenase-2 expression in intestinal epithelial cells through small GTPases using distinct signaling pathways. J. Biol. Chem. 280, 1582-1593 (2005)
88. J. M. David, C. Dominguez, D. H. Hamilton, C. Palena, The IL-8/IL-8R axis: A double agent in tumor immune resistance. Vaccines 4, E22 (2016)
89. F. Martin, L. Apetoh, F. Ghiringhelli, Controversies on the role of Th17 in cancer: A TGF-b-dependent immunosuppressive activity? Trends Mol. Med. 18, 742-749 (2012)
90. S. Ugel, F. Sanctis, S. Mandruzzato, V. Bronte, Tumor-induced myeloid deviation: When myeloid-derived suppressor cells meet tumor-associated macrophages. J. Clin. Invest. 125, 3365-3376 (2015)
91. D. S. Vinay, E. P. Ryan, G. Pawelec, W. H. Talib, J. Stagg, E. Elkord, T. Lichtor, W. K. Decker, R. L. Whelan, H. M. C. S. Kumara, E. Signori, K. Honoki, A. G. Georgakilas, A. Amin, W. G. Helferich, C. S. Boosani, G. Guha, M. R. Ciriolo, S. Chen, S. I. Mohammed, A. S. Azmi, W. N. Keith, A. Bilsland, D. Bhakta, D. Halicka, H. Fujii, K. Aquilano, S. S. Ashraf, S. Nowsheen, X. Yang, B. K. Choi, B. S. Kwon, Immune evasion in cancer: Mechanistic basis and therapeutic strategies. Semin. Cancer Biol. 35 (Suppl), S185-S198 (2015)
92. J. R. Brown, R. N. DuBois, COX-2: A molecular target for colorectal cancer prevention. J. Clin. Oncol. 23, 2840-2855 (2005)
93. S. Zelenay, A. G. van der Veen, J. P. Böttcher, K. J. Snelgrove, N. Rogers, S. E. Acton, P. Chakravarty, M. R. Girotti, R. Marais, S. A. Quezada, E. Sahai, C. Reis Sousa, Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257-1270 (2015)
94. H. Frenzel, R. Pries, C. P. Brocks, W. J. Jabs, N. Wittkopf, B. Wollenberg, Decreased migration of myeloid dendritic cells through increased levels of C-reactive protein. Anticancer Res. 27, 4111-4115 (2007)
95. S. H. Jackson, S. Devadas, J. Kwon, L. A. Pinto, M. S. Williams, T cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulation. Nat. Immunol. 5, 818-827 (2004)
96. L. A. Sena, S. Li, A. Jairaman, M. Prakriya, T. Ezponda, D. A. Hildeman, C.-R. Wang, P. T. Schumacker, J. D. Licht, H. Perlman, P. J. Bryce, N. S. Chandel, Mitochondria are required for antigen-specific T cell activation through reactive oxygen species signaling. Immunity 38, 225-236 (2013)
97. S. I. Gringhuis, A. Leow, E. A. M. Papendrecht-Voort, P. H. J. Remans, F. C. Breedveld, C. L. Verweij, Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J. Immunol. 164, 2170-2179 (2000)
98. N. Lahdenpohja, K. Savinainen, M. Hurme, Pre-exposure to oxidative stress decreases the nuclear factor-kB-dependent transcription in T lymphocytes. J. Immunol. 160, 1354-1358 (1998)
99. H.-R. Kim, A. Lee, E.-J. Choi, M.-P. Hong, J.-H. Kie, W. Lim, H. K. Lee, B.-I. Moon, J.-Y. Seoh, Reactive oxygen species prevent imiquimod-induced psoriatic dermatitis through enhancing regulatory T cell function. PLOS ONE 9, e91146 (2014)
100. X. Lin, W. Zheng, J. Liu, Y. Zhang, H. Qin, H. Wu, B. Xue, Y. Lu, P. Shen, Oxidative stress in malignant melanoma enhances tumor necrosis factor-A secretion of tumor-associated macrophages that promote cancer cell invasion. Antioxid. Redox Signal. 19, 1337-1355 (2013)
101. A. Sica, T. Schioppa, A. Mantovani, P. Allavena, Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur. J. Cancer 42, 717-727 (2006)
102. H. Uemura, H. Ishiguro, Y. Ishiguro, K. Hoshino, S. Takahashi, Y. Kubota, Angiotensin II induces oxidative stress in prostate cancer. Mol. Cancer Res. 6, 250-258 (2008)
103. S. Shirotake, A. Miyajima, T. Kosaka, N. Tanaka, E. Kikuchi, S. Mikami, Y. Okada, M. Oya, Regulation of monocyte chemoattractant protein-1 through angiotensin II type 1 receptor in prostate cancer. Am. J. Pathol. 180, 1008-1016 (2012)
104. K. Egami, T. Murohara, T. Shimada, K.-i. Sasaki, S. Shintani, T. Sugaya, M. Ishii, T. Akagi, H. Ikeda, T. Matsuishi, T. Imaizumi, Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J. Clin. Invest. 112, 67-75 (2003)
105. N. Chehl, Q. Gong, G. Chipitsyna, T. Aziz, C. J. Yeo, H. A. Arafat, Angiotensin II regulates the expression of monocyte chemoattractant protein-1 in pancreatic cancer cells. J. Gastrointest. Surg. 13, 2189-2200 (2009)
106. X. Z. Shen, K. E. Bernstein, The peptide network regulated by angiotensin converting enzyme (ACE) in hematopoiesis. Cell Cycle 10, 1363-1369 (2011)
107. X. Z. Shen, D. Okwan-Duodu, W.-L. Blackwell, F. S. Ong, T. Janjulia, E. A. Bernstein, S. Fuchs, S. Alkan, K. E. Bernstein, Myeloid expression of angiotensin-converting enzyme facilitates myeloid maturation and inhibits the development of myeloid-derived suppressor cells. Lab. Invest. 94, 536-544 (2014)
108. X. Z. Shen, P. Li, D. Weiss, S. Fuchs, H. D. Xiao, J. A. Adams, I. R. Williams, M. R. Capecchi, W. R. Taylor, K. E. Bernstein, Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am. J. Pathol. 170, 2122-2134 (2007)
109. X. Z. Shen, A. E. Lukacher, S. Billet, I. R. Williams, K. E. Bernstein, Expression of angiotensin-converting enzyme changes major histocompatibility complex class I peptide presentation by modifying C termini of peptide precursors. J. Biol. Chem. 283, 9957-9965 (2008)
110. L. Hofmann, A. Forschner, C. Loquai, S. M. Goldinger, L. Zimmer, S. Ugurel, M. I. Schmidgen, R. Gutzmer, J. S. Utikal, D. Göppner, J. C. Hassel, F. Meier, J. K. Tietze, I. Thomas, C. Weishaupt, M. Leverkus, R. Wahl, U. Dietrich, C. Garbe, M. C. Kirchberger, T. Eigentler, C. Berking, A. Gesierich, A. M. Krackhardt, D. Schadendorf, G. Schuler, R. Dummer, L. M. Heinzerling, Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur. J. Cancer 60, 190-209 (2016)
111. M. A. Postow, J. Chesney, A. C. Pavlick, C. Robert, K. Grossmann, D. McDermott, G. P. Linette, N. Meyer, J. K. Giguere, S. S. Agarwala, M. Shaheen, M. S. Ernstoff, D. Minor, A. K. Salama, M. Taylor, P. A. Ott, L. M. Rollin, C. Horak, P. Gagnier, J. D. Wolchok, F. S. Hodi, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med. 372, 2006-2017 (2015)
112. M. N. Bouchlaka, G. D. Sckisel, M. Chen, A. Mirsoian, A. E. Zamora, E. Maverakis, D. E. C. Wilkins, K. L. Alderson, H.-H. Hsiao, J. M. Weiss, A. M. Monjazeb, C. Hesdorffer, L. Ferrucci, D. L. Longo, B. R. Blazar, R. H. Wiltrout, D. Redelman, D. D. Taub, W. J. Murphy, Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy. J. Exp. Med. 210, 2223-2237 (2013)
113. A. Mirsoian, M. N. Bouchlaka, G. D. Sckisel, M. Chen, C.-C. S. Pai, E. Maverakis, R. G. Spencer, K. W. Fishbein, S. Siddiqui, A. M. Monjazeb, B. Martin, S. Maudsley, C. Hesdorffer, L. Ferrucci, D. L. Longo, B. R. Blazar, R. H. Wiltrout, D. D. Taub, W. J. Murphy, Adiposity induces lethal cytokine storm after systemic administration of stimulatory immunotherapy regimens in aged mice. J. Exp. Med. 211, 2373-2383 (2014)
114. D. Fliser, K. Buchholz, H. Haller; EUropean Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators, Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 110, 1103-1107 (2004)
115. S. Manabe, T. Okura, S. Watanabe, T. Fukuoka, J. Higaki, Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension. J. Cardiovasc. Pharmacol. 46, 735-739 (2005)
116. M. G. Pavlatou, G. Mastorakos, A. Margeli, E. Kouskouni, N. Tentolouris, N. Katsilambros, G. P. Chrousos, I. Papassotiriou, Angiotensin blockade in diabetic patients decreases insulin resistance-associated low-grade inflammation. Eur. J. Clin. Invest. 41, 652-658 (2011)
117. M. D. Holmes, S. E. Hankinson, D. Feskanich, W. Y. Chen, Beta blockers and angiotensinconverting enzyme inhibitors' purported benefit on breast cancer survival may be explained by aspirin use. Breast Cancer Res. Treat. 139, 507-513 (2013)
118. P. H. Jones, K. Christodoulos, N. Dobbs, P. Thavasu, F. Balkwill, A. D. Blann, G. J. Caine, S. Kumar, A. J. Kakkar, N. Gompertz, D. C. Talbot, T. S. Ganesan, A. L. Harris, Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer. Br. J. Cancer 91, 30-36 (2004)
119. Y. Nakai, H. Isayama, H. Ijichi, T. Sasaki, H. Kogure, H. Yagioka, K. Miyabayashi, S. Mizuno, K. Yamamoto, D. Mouri, K. Kawakubo, N. Yamamoto, K. Hirano, N. Sasahira, K. Tateishi, M. Tada, K. Koike, Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Cancer Sci. 103, 1489-1492 (2012)
120. Y. Nakai, H. Isayama, H. Ijichi, T. Sasaki, N. Takahara, Y. Ito, S. Matsubara, R. Uchino, H. Yagioka, T. Arizumi, T. Hamada, K. Miyabayashi, S. Mizuno, K. Yamamoto, H. Kogure, N. Yamamoto, K. Hirano, N. Sasahira, K. Tateishi, M. Tada, K. Koike, A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Invest. New Drugs 31, 1294-1299 (2013)
121. G. Ronquist, G. Frithz, Y.-H. Wang, T. Lindeborg, Captopril may reduce biochemical (prostate-specific antigen) failure following radical prostatectomy for clinically localized prostate cancer. Scand. J. Urol. Nephrol. 43, 32-36 (2009)
122. G. V. Sørensen, P. A. Ganz, S. W. Cole, L. A. Pedersen, H. T. Sørensen, D. P. Cronin-Fenton, J. P. Garne, P. M. Christiansen, T. L. Lash, T. P. Ahern, Use of b-blockers, angiotensinconverting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: A Danish nationwide prospective cohort study. J. Clin. Oncol. 31, 2265-2272 (2013)
123. M. Tatokoro, Y. Fujii, S. Kawakami, K. Saito, F. Koga, Y. Matsuoka, Y. Iimura, H. Masuda, K. Kihara, Phase-II trial of combination treatment of interferon a, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 102, 137-143 (2011)
124. H. Uemura, H. Hasumi, T. Kawahara, S. Sugiura, Y. Miyoshi, N. Nakaigawa, J.-i. Teranishi, K. Noguchi, H. Ishiguro, Y. Kubota, Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int. J. Clin. Oncol. 10, 405-410 (2005)
125. H. Yoshiji, R. Noguchi, Y. Ikenaka, K. Kaji, Y. Aihara, M. Yamazaki, J. Yamao, M. Toyohara, A. Mitoro, M. Sawai, M. Yoshida, C. Morioka, M. Fujimoto, M. Uemura, H. Fukui, Combination of branched-chain amino acids and angiotensin-converting enzyme inhibitor suppresses the cumulative recurrence of hepatocellular carcinoma: A randomized control trial. Oncol. Rep. 26, 1547-1553 (2011)
126. H. Yoshiji, R. Noguchi, M. Toyohara, Y. Ikenaka, M. Kitade, K. Kaji, M. Yamazaki, J. Yamao, A. Mitoro, M. Sawai, M. Yoshida, M. Fujimoto, T. Tsujimoto, H. Kawaratani, M. Uemura, H. Fukui, Combination of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates cumulative recurrence of hepatocellular carcinoma. J. Hepatol. 51, 315-321 (2009)
127. A. Alashkham, C. Paterson, P. Windsor, A. Struthers, P. Rauchhaus, G. Nabi, The incidence and risk of biochemical recurrence following radical radiotherapy for prostate cancer in men on angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Clin. Genitourin. Cancer 14, 398-405 (2016)
128. A. Aydiner, R. Ciftci, F. Sen, Renin-Angiotensin system blockers may prolong survival of metastatic non-small cell lung cancer patients receiving erlotinib. Medicine 94, e887 (2015)
129. T. Babacan, O. Balakan, T. Y. Kuzan, F. Sarici, E. Koca, N. Kertmen, I. Petekkaya, K. Altundag, The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients. J. BUON 20, 50-56 (2015)
130. M. L. Blute Jr., T. J. Rushmer, F. Shi, B. J. Fuller, E. J. Abel, D. F. Jarrard, T. M. Downs, Renin-angiotensin inhibitors decrease recurrence after transurethral resection of bladder tumor in patients with nonmuscle invasive bladder cancer. J. Urol. 194, 1214-1219 (2015)
131. E. Botteri, E. Munzone, N. Rotmensz, C. Cipolla, V. De Giorgi, B. Santillo, A. Zanelotti, L. Adamoli, M. Colleoni, G. Viale, A. Goldhirsch, S. Gandini, Therapeutic effect of b-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res. Treat. 140, 567-575 (2013)
132. D. M. Boudreau, O. Yu, J. Chubak, H. S. Wirtz, E. J. A. Bowles, M. Fujii, D. S. M. Buist, Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer. Breast Cancer Res. Treat. 144, 405-416 (2014)
133. Y. K. Chae, E. N. Brown, X. Lei, A. Melhem-Bertrandt, S. H. Giordano, J. K. Litton, G. N. Hortobagyi, A. M. Gonzalez-Angulo, M. Chavez-MacGregor, Use of ACE inhibitors and angiotensin receptor blockers and primary breast cancer outcomes. J. Cancer 4, 549-556 (2013)
134. Y. K. Chae, M. E. Valsecchi, J. Kim, A. L. Bianchi, D. Khemasuwan, A. Desai, W. Tester, Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins. Cancer Invest. 29, 585-593 (2011)
135. P. A. Ganz, L. A. Habel, E. K. Weltzien, B. J. Caan, S. W. Cole, Examining the influence of beta blockers and ACE inhibitors on the risk for breast cancer recurrence: Results from the LACE cohort. Breast Cancer Res. Treat. 129, 549-556 (2011)
136. H. Goldvaser, S. Rizel, D. Hendler, V. Neiman, D. Shepshelovich, T. Shochat, A. Sulkes, B. Brenner, R. Yerushalmi, The association between angiotensin receptor blocker usage and breast cancer characteristics. Oncology 91, 217-223 (2016)
137. H. Izzedine, L. Derosa, G. Le Teuff, L. Albiges, B. Escudier, Hypertension and angiotensin system inhibitors: Impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma. Ann. Oncol. 26, 1128-1133 (2015)
138. D. Keizman, M. Gottfried, M. Ish-Shalom, N. Maimon, A. Peer, A. Neumann, H. Hammers, M. A. Eisenberger, V. Sinibaldi, R. Pili, H. Hayat, S. Kovel, A. Sella, B. Boursi, R. Weitzen, W. Mermershtain, K. Rouvinov, R. Berger, M. A. Carducci, Active smoking may negatively affect response rate, progression-free survival, and overall survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 19, 51-60 (2014)
139. D. Keizman, P. Huang, M. A. Eisenberger, R. Pili, J. J. Kim, E. S. Antonarakis, H. Hammers, M. A. Carducci, Angiotensin system inhibitors and outcome of sunitinib treatment in patients with metastatic renal cell carcinoma: A retrospective examination. Eur. J. Cancer 47, 1955-1961 (2011)
140. R. R. McKay, G. E. Rodriguez, X. Lin, M. D. Kaymakcalan, O.-P. R. Hamnvik, V. S. Sabbisetti, R. S. Bhatt, R. Simantov, T. K. Choueiri, Angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin. Cancer Res. 21, 2471-2479 (2015)
141. A. Melhem-Bertrandt, M. Chavez-MacGregor, X. Lei, E. N. Brown, R. T. Lee, F. Meric-Bernstam, A. K. Sood, S. D. Conzen, G. N. Hortobagyi, A. M. Gonzalez-Angulo, Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J. Clin. Oncol. 29, 2645-2652 (2011)
142. A. R. Menter, N. M. Carroll, L. C. Sakoda, T. Delate, M. C. Hornbrook, R. K. Jain, L. H. Kushi, V. P. Quinn, D. P. Ritzwoller, Effect of angiotensin system inhibitors on survival in patients receiving chemotherapy for advanced non-small-cell lung cancer. Clin. Lung Cancer 18, 189-197 (2017)
143. L. Miao, W. Chen, L. Zhou, H. Wan, B. Gao, Y. Feng, Impact of angiotensin I-converting enzyme inhibitors and angiotensin II type-1 receptor blockers on survival of patients with NSCLC. Sci. Rep. 6, 21359 (2016)
144. A. Miyajima, S. Yazawa, T. Kosaka, N. Tanaka, S. Shirotake, R. Mizuno, E. Kikuchi, M. Oya, Prognostic impact of renin-angiotensin system blockade on renal cell carcinoma after surgery. Ann. Surg. Oncol. 22, 3751-3759 (2015)
145. M. A. N. Sendur, S. Aksoy, S. Yaman, N. Y. Ozdemir, N. Zengin, K. Altundag, Efficacy of angiotensin-receptor blockers on demographic and clinico-pathological characteristics of breast cancer. Breast 21, 419-420 (2012)
146. M. J. Sorich, G. Kichenadasse, A. Rowland, R. J. Woodman, A. A. Mangoni, Angiotensin system inhibitors and survival in patients with metastatic renal cell carcinoma treated with VEGF-targeted therapy: A pooled secondary analysis of clinical trials. Int. J. Cancer 138, 2293-2299 (2016)
147. N. Tanaka, A. Miyajima, E. Kikuchi, K. Matsumoto, M. Hagiwara, H. Ide, T. Kosaka, T. Masuda, S. Nakamura, M. Oya, Prognostic impact of renin-angiotensin system blockade in localised upper-tract urothelial carcinoma. Br. J. Cancer 106, 290-296 (2012)
148. H. Wang, Z. Liao, Y. Zhuang, Y. Liu, L. B. Levy, T. Xu, S. W. Yusuf, D. R. Gomez, Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy. Clin. Lung Cancer 16, 128-136 (2015)
149. S. Wilop, S. von Hobe, M. Crysandt, A. Esser, R. Osieka, E. Jost, Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinumbased chemotherapy. J. Cancer Res. Clin. Oncol. 135, 1429-1435 (2009)
150. T. Yoshida, H. Kinoshita, K. Fukui, T. Matsuzaki, K. Yoshida, T. Mishima, M. Yanishi, Y. Komai, M. Sugi, T. Inoue, T. Murota, T. Matsuda, Prognostic impact of reninangiotensin inhibitors in patients with bladder cancer undergoing radical cystectomy. Ann. Surg. Oncol. 24, 823-831 (2017)
151. K. Yuge, A. Miyajima, N. Tanaka, S. Shirotake, T. Kosaka, E. Kikuchi, M. Oya, Prognostic value of renin-angiotensin system blockade in non-muscle-invasive bladder cancer. Ann. Surg. Oncol. 19, 3987-3993 (2012)
152. T. Buchler, M. Krejci, A. Svobodnik, Z. Adam, J. Minarik, J. Bacovsky, V. Scudla, J. Mayer, J. Vorlicek, R. Hajek, Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy. Hematol. J. 5, 559-564 (2005)
153. C. R. Cardwell, U. C. Mc Menamin, B. M. Hicks, C. Hughes, M. M. Cantwell, L. J. Murray, Drugs affecting the renin-angiotensin system and survival from cancer: A population based study of breast, colorectal and prostate cancer patient cohorts. BMC Med. 12, 28 (2014)
154. A. F. Carpentier, D. Ferrari, O. Bailon, R. Ursu, C. Banissi, A.-L. Dubessy, C. Belin, C. Levy, Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients. Eur. J. Neurol. 19, 1337-1342 (2012)
155. Y. K. Chae, A. Dimou, S. Pierce, H. Kantarjian, M. Andreeff, The effect of calcium channel blockers on the outcome of acute myeloid leukemia. Leuk. Lymphoma 55, 2822-2829 (2014)
156. Y.-H. Chen, C.-H. Huang, H.-I. Lu, C.-H. Chen, W.-T. Huang, M.-J. Hsieh, K.-M. Rau, A. Y. W. Chang, W.-C. Lin, S.-H. Li, Prognostic impact of renin-angiotensin system blockade in esophageal squamous cell carcinoma. J. Renin Angiotensin Aldosterone Syst. 16, 1185-1192 (2015)
157. V. Giorgi, S. Gandini, M. Grazzini, S. Benemei, N. Marchionni, P. Geppetti, Effect of b-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death. Mayo Clin. Proc. 88, 1196-1203 (2013)
158. D. R. Engineer, B. O. Burney, T. G. Hayes, J. M. Garcia, Exposure to ACEI/ARB and b-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl. Oncol. 6, 539-545 (2013)
159. A. Facciorusso, V. Del Prete, N. Crucinio, N. Muscatiello, B. I. Carr, A. Di Leo, M. Barone, Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J. Gastroenterol. Hepatol. 30, 1643-1650 (2015)
160. L.-R. He, W. Qiao, Z.-X. Liao, R. Komaki, L. Ho, W. L. Hofstetter, S. H. Lin, Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma. BMC Cancer 15, 1095 (2015)
161. J. H. Heinzerling, T. Anthony, E. H. Livingston, S. Huerta, Predictors of distant metastasis and mortality in patients with stage II colorectal cancer. Am. Surg. 73, 230-238 (2007)
162. S. Holmes, E. J. Griffith, G. Musto, G. Y. Minuk, Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study. Cancer Epidemiol. 37, 881-885 (2013)
163. E. Januel, R. Ursu, A. Alkhafaji, A. Marantidou, J. Doridam, C. Belin, C. Levy-Piedbois, A. F. Carpentier, Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma. Eur. J. Neurol. 22, 1304-1309 (2015)
164. M. Kaibori, M. Ishizaki, K. Matsui, H. Kitade, Y. Matsui, A.-H. Kwon, Evaluation of metabolic factors on the prognosis of patients undergoing resection of hepatocellular carcinoma. J. Gastroenterol. Hepatol. 26, 536-543 (2011)
165. S. T. Kim, K. H. Park, S. C. Oh, J. H. Seo, J. S. Kim, S. W. Shin, Y. H. Kim, How does inhibition of the renin-angiotensin system affect the prognosis of advanced gastric cancer patients receiving platinum-based chemotherapy? Oncology 83, 354-360 (2012)
166. A. Kourilsky, G. Bertrand, R. Ursu, J. Doridam, C. Barlog, T. Faillot, E. Mandonnet, C. Belin, C. Levy, A. F. Carpentier, Impact of angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients. J. Neurol. 263, 524-530 (2016)
167. Z. S. Morris, S. Saha, W. J. Magnuson, B. A. Morris, J. F. Borkenhagen, A. Ching, G. Hirose, V. McMurry, D. M. Francis, P. M. Harari, R. Chappell, S. Tsuji, M. A. Ritter, Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer 122, 2487-2495 (2016)
168. Y. Nakai, H. Isayama, H. Ijichi, T. Sasaki, N. Sasahira, K. Hirano, H. Kogure, K. Kawakubo, H. Yagioka, Y. Yashima, S. Mizuno, K. Yamamoto, T. Arizumi, O. Togawa, S. Matsubara, T. Tsujino, K. Tateishi, M. Tada, M. Omata, K. Koike, Inhibition of renin-angiotensin system affects prognosis of advanced pancreatic cancer receiving gemcitabine. Br. J. Cancer 103, 1644-1648 (2010)
169. Y. Nakai, H. Isayama, T. Sasaki, S. Mizuno, N. Sasahira, H. Kogure, K. Kawakubo, N. Yamamoto, K. Hirano, H. Ijichi, K. Tateishi, M. Tada, K. Koike, Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: Better prognosis with statin use in diabetic patients. Pancreas 42, 202-208 (2013)
170. Y. Nakai, H. Isayama, T. Sasaki, N. Takahara, K. Saito, K. Ishigaki, T. Hamada, S. Mizuno, K. Miyabayashi, K. Yamamoto, D. Mohri, H. Kogure, N. Yamamoto, H. Ijichi, K. Tateishi, M. Tada, K. Koike, The inhibition of renin-angiotensin system in advanced pancreatic cancer: An exploratory analysis in 349 patients. J. Cancer Res. Clin. Oncol. 141, 933-939 (2015)
171. Y. Nakai, H. Isayama, T. Sasaki, N. Takahara, K. Saito, T. Takeda, G. Umefune, T. Saito, K. Takagi, T. Watanabe, T. Hamada, R. Uchino, S. Mizuno, K. Yamamoto, H. Kogure, S. Matsubara, N. Yamamoto, H. Ijichi, K. Tateishi, M. Tada, K. Koike, No survival benefit from the inhibition of renin-angiotensin system in biliary tract cancer. Anticancer Res. 36, 4965-4970 (2016)
172. H. Osumi, S. Matsusaka, T. Wakatsuki, M. Suenaga, E. Shinozaki, N. Mizunuma, Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol. Clin. Oncol. 3, 1295-1300 (2015)
173. M. Pinter, A. Weinmann, M.-A. Wörns, F. Hucke, S. Bota, J. U. Marquardt, D. G. Duda, R. K. Jain, P. R. Galle, M. Trauner, M. Peck-Radosavljevic, W. Sieghart, Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. United European Gastroenterol. J. 10.1177/2050640617695698 (2017)
174. S. J. Tingle, J. A. Moir, S. A. White, Role of anti-stromal polypharmacy in increasing survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. World J Gastrointest Pathophysiol 6, 235-242 (2015)
175. V. A. Levin, J. Chan, M. Datta, J. L. Yee, R. K. Jain, Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. J. Neurooncol. 134, 325-330 (2017)
176. N. Tanaka, A. Miyajima, T. Kosaka, S. Shirotake, M. Hasegawa, E. Kikuchi, M. Oya, Cis-dichlorodiammineplatinum upregulates angiotensin II type 1 receptors through reactive oxygen species generation and enhances VEGF production in bladder cancer. Mol. Cancer Ther. 9, 2982-2992 (2010)
177. N. Tanaka, A. Miyajima, T. Kosaka, Y. Miyazaki, S. Shirotake, H. Shirakawa, E. Kikuchi, M. Oya, Acquired platinum resistance enhances tumour angiogenesis through angiotensin II type 1 receptor in bladder cancer. Br. J. Cancer 105, 1331-1337 (2011)
178. M. M. Abd-Alhaseeb, S. A. Zaitone, S. H. Abou-Ela, Y. M. Moustafa, Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: Role of angiotensin (1-7). PLOS ONE 9, e85891 (2014)
179. M. R. Mancuso, R. Davis, S. M. Norberg, S. O'Brien, B. Sennino, T. Nakahara, V. J. Yao, T. Inai, P. Brooks, B. Freimark, D. R. Shalinsky, D. D. Hu-Lowe, D. M. McDonald, Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest. 116, 2610-2621 (2006)
180. A. W. Griffioen, L. A. Mans, A. M. A. Graaf, P. Nowak-Sliwinska, C. L. M. M. Hoog, T. A. M. Jong, F. A. Vyth-Dreese, J. R. van Beijnum, A. Bex, E. Jonasch, Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Clin. Cancer Res. 18, 3961-3971 (2012)
181. W. D. Fox, B. Higgins, K. M. Maiese, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, D. B. Agus, Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin. Cancer Res. 8, 3226-3231 (2002)
182. T. Powles, C. Blank, S. Chowdhury, S. Horenblas, J. Peters, J. Shamash, N. Sarwar, E. Boleti, A. Sahdev, T. O'Brien, D. Berney, L. Beltran, P. Nathan, J. Haanen, A. Bex, The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer. Eur. Urol. 60, 448-454 (2011)
183. B. I. Rini, J. Bellmunt, J. Clancy, K. Wang, A. G. Niethammer, S. Hariharan, B. Escudier, Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J. Clin. Oncol. 32, 752-759 (2014)
184. N. B. Haas, J. Manola, R. G. Uzzo, K. T. Flaherty, C. G. Wood, C. Kane, M. Jewett, J. P. Dutcher, M. B. Atkins, M. Pins, G. Wilding, D. Cella, L. Wagner, S. Matin, T. M. Kuzel, W. J. Sexton, Y.-N. Wong, T. K. Choueiri, R. Pili, I. Puzanov, M. Kohli, W. Stadler, M. Carducci, R. Coomes, R. S. DiPaola, Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387, 2008-2016 (2016)
185. A. Ravaud, M. Schmidinger, Clinical biomarkers of response in advanced renal cell carcinoma. Ann. Oncol. 24, 2935-2942 (2013)
186. S. Raimondi, E. Botteri, E. Munzone, C. Cipolla, N. Rotmensz, A. DeCensi, S. Gandini, Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: Systematic review and meta-analysis. Int. J. Cancer 139, 212-219 (2016)
187. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer, EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012)
188. M. G. Fakih, Metastatic colorectal cancer: Current state and future directions. J. Clin. Oncol. 33, 1809-1824 (2015)
189. B. Escudier, C. Porta, M. Schmidinger, N. Rioux-Leclercq, A. Bex, V. Khoo, V. Gruenvald, A. Horwich; ESMO Guidelines Committee, Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (suppl. 5), v58-v68 (2016)
190. J. E. Faris, L. S. Blaszkowsky, S. McDermott, A. R. Guimaraes, J. Szymonifka, M. A. Huynh, C. R. Ferrone, J. A. Wargo, J. N. Allen, L. E. Dias, E. L. Kwak, K. D. Lillemoe, S. P. Thayer, J. E. Murphy, A. X. Zhu, D. V. Sahani, J. Y. Wo, J. W. Clark, C. Fernandez-Castillo, D. P. Ryan, T. S. Hong, FOLFIRINOX in locally advanced pancreatic cancer: The Massachusetts General Hospital Cancer Center experience. Oncologist 18, 543-548 (2013)
191. E. A. Mellon, S. E. Hoffe, G. M. Springett, J. M. Frakes, T. J. Strom, P. J. Hodul, M. P. Malafa, M. D. Chuong, R. Shridhar, Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma. Acta Oncol. 54, 979-985 (2015)
192. T. Song, C. H. Choi, M. K. Kim, M.-L. Kim, B. S. Yun, S. J. Seong, The effect of angiotensin system inhibitors (angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) on cancer recurrence and survival: A meta-analysis. Eur. J. Cancer Prev. 26, 78-85 (2017)
193. M. Pinter, M. Trauner, M. Peck-Radosavljevic, W. Sieghart, Cancer and liver cirrhosis: Implications on prognosis and management. ESMO Open 1, e000042 (2016)
194. H. Yoshiji, S. Kuriyama, J. Yoshii, Y. Ikenaka, R. Noguchi, T. Nakatani, H. Tsujinoue, H. Fukui, Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology 34, 745-750 (2001)
195. J. R. Jonsson, A. D. Clouston, Y. Ando, L. I. Kelemen, M. J. Horn, M. D. Adamson, D. M. Purdie, E. E. Powell, Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121, 148-155 (2001)
196. P. Tandon, J. G. Abraldes, A. Berzigotti, J. C. Garcia-Pagan, J. Bosch, Renin-angiotensinaldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis. J. Hepatol. 53, 273-282 (2010)
197. R. K. Jain, Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nat. Rev. Cancer 8, 309-316 (2008)